Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 25,000 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $5.24, for a total value of $131,000.00. Following the transaction, the chief executive officer owned 1,190,067 shares of the company’s stock, valued at approximately $6,235,951.08. The trade was a 2.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, September 29th, Vishwas Seshadri sold 19,274 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.39, for a total value of $103,886.86.
• On Wednesday, July 9th, Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.86, for a total transaction of $406,801.20.

Abeona Therapeutics Stock Performance

ABEO stock opened at $5.28 on Thursday. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54. The firm’s 50-day moving average is $6.41 and its 200 day moving average is $5.92. The company has a market capitalization of $270.76 million, a PE ratio of 7.54 and a beta of 1.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million. On average, research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ABEO shares. Oppenheimer upped their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $19.50.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds have recently made changes to their positions in the stock. Trexquant Investment LP grew its stake in Abeona Therapeutics by 74.1% in the first quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 50,758 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $520,000. Goldman Sachs Group Inc. grew its position in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after buying an additional 66,422 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $67,000. Finally, Newtyn Management LLC lifted its position in Abeona Therapeutics by 26.3% during the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock valued at $2,285,000 after acquiring an additional 100,000 shares during the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.